Clinical trial · Observational
Improving End of Life Care in Head and Neck Cancer
NCT01632969CI-TRIAL-00017028terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of accrual
Summary
Brief summary (as posted)
The purpose of this study is to improve the quality of care provided for head and neck cancer patients. By better understanding the end of life experiences of dying patients and their families, the investigators hope to better anticipate and improve upon the experiences of future patients and their families.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| The Families or Next of Kin of Patients Treated at MSKCC for Non-cutaneous Squamous Cell Carcinomas of the | — | UNRESOLVED | — |
| Upper Aerodigestive Tract | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| The The Family Assessment of Treatment at the End of life (FATE ) survey | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- families or next-of-kin of deceased patients
- description
- The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
- interventionNames
- Behavioral: The The Family Assessment of Treatment at the End of life (FATE ) survey
Primary outcomes (1)
- measure
- quality of care received by patients
- timeFrame
- 1 year
- description
- To determine the perception of the family members of the quality of care received by patients with aerodigestive mucosal squamous cell carcinoma of the head and neck at the end of their lives. A survey will be administered to the families and next-of-kin of deceased patients. A recently validated survey instrument, the Family Assessment of Treatment at the End of life (FATE), is designed to assess treatment at the end of life based upon the responses of family members of the deceased (Finlay, Shreve et al. 2008).
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Head and neck cancer patients who received their treatment at MSKCC who have died of noncutaneous squamous cell carcinomas of the upper aerodigestive tract and for whom family / next of kin contact information is available. * Time of patient death must have been at least 6 months ago and no more than 4 years ago * Patient age at time of death must be over 21 years of age. * Those interviewed must be English-fluent. Exclusion Criteria: * Non-English speaking interviewees * Next-of-kin who reported being unfamiliar with care received during the last month of life * Next-of-kin who did not identify themselves as one of the patient's primary social supports during the last month of life * Next-of-kin who were not physically present with the deceased at least once during the last week of his/her life * Next-of-kin under age 21
References
Publications (0)
Data not yet available
No reference posted for this study.